Besides this known mode of action, our present observations indicate that PTXF may directly modify the cell populations within the central nervous system via c-REL-inhibition in vivo, which is of potential interest for treating not only multiple sclerosis but also schizophrenia, i.e., diseases where the number of oligodendrocytes in the brain is decreased [43]. The gene discussed is REL; the disease is schizophrenia.